New Release: Cain by Ellis Ink Offers a Modern Twist on the Classic Biblical Tale of Sibling Rivalry and Greed

New Release: Cain by Ellis Ink Offers a Modern Twist on the Classic Biblical Tale of Sibling Rivalry and Greed

Cain, the debut novel by Ellis Ink, brings a fresh and contemporary spin to the timeless story of Cain and Abel, casting it in the context of modern family dynamics, wealth, and corporate power. Released in May, 2023, Cain dives deep into the complexities of sibling relationships, jealousy, and the high-stakes world of family inheritance.

Cain follows the lives of Nathaniel (Nate) and Gabriel (Gabe) Whittmen, two brothers poised to inherit their father’s billion-dollar empire. When their father, Henry Whittmen, is diagnosed with terminal cancer, the brothers are faced with a life-changing challenge: whoever manages the family business best will take over as CEO. But what starts as a test of business acumen quickly spirals into a bitter and dangerous rivalry. Nate, consumed by ambition and greed, resorts to unethical practices to gain control, while Gabe focuses on his family’s legacy and the values instilled by his father.

Ellis Ink crafts a compelling narrative that echoes the themes of sibling rivalry and moral conflict, while offering a poignant examination of how power, greed, and jealousy can tear families apart. The novel is a powerful meditation on the consequences of ambition when it goes unchecked, as well as a tribute to the enduring lessons of one of history’s oldest stories.

“I wanted to show that, while times may change, the core struggles we face as human beings remain the same,” said Ellis Ink. “In Cain, I hope readers will recognize themselves and their own family dynamics, and perhaps learn the importance of integrity, love, and forgiveness in the face of life’s challenges.”

About the Author

Ellis Ink is a New York-based writer, director, and entertainer with years of experience in the performing arts. With Cain, she channels her passion for storytelling and deep understanding of human nature into a gripping novel that will resonate with readers of all backgrounds.

Cain is available now in paperback, e-book, and audiobook formats. For more information, visit www.ellisinkbooks.com or contact the author directly at info@ellisinkbooks.com.

Book Name: Cain

Author Name: Pamela Ellis

ISBN Number: 1916626076

Paperback Version: Click Here

Media Contact
Company Name: Amazon Publishing Hub
Email: Send Email
Phone: 844-727-0033
Country: United States
Website: https://www.amazonpublishinghub.com/

Methicillin-resistant Staphylococcus aureus (MRSA) Infection Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Methicillin-Resistant Staphylococcus Aureus Infection Research. Learn more about our innovative pipeline today! @ Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Outlook

 

Key Takeaways from the Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Report

  • In September 2024:- AbbVie- A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections. To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
  • DelveInsight’s Methicillin-Resistant Staphylococcus Aureus Infection pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Methicillin-Resistant Staphylococcus Aureus Infection treatment.
  • The leading Methicillin-Resistant Staphylococcus Aureus Infection Companies such as Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
  • Promising Methicillin-Resistant Staphylococcus Aureus Infection Therapies such as Retapamulin, Linezolid (Zyvox), Vancomycin, Nitric Oxide, Ceftaroline fosamil, Daptomycin, and others.

 

Stay informed about the cutting-edge advancements in Methicillin-Resistant Staphylococcus Aureus Infection Treatments. Download for updates and be a part of the revolution in care @ Methicillin-Resistant Staphylococcus Aureus Infection Clinical Trials Assessment

 

Methicillin-Resistant Staphylococcus Aureus Infection Emerging Drugs Profile

  • HY-004B8b: Helperby Therapeutics

Helperby has discovered and is developing a suite of Antibiotic Resistance Breakers (ARBs). These compounds, when combined with old antibiotics, can restore the original potency against both Gram positive and Gram negative bacteria. Helperby’s HY-004 project is in phase II trials for effectiveness against nasal MRSA decolonisation.

  • TRL1068: Trellis Bioscience

TRL1068 is a high affinity mAb that targets the DNABII protein family; BLAST analysis has found hundreds of DNABII homologs across many bacterial species. TRL1068 is broad-spectrum, disrupting biofilm across multiple gram-positive and gram-negative bacteria species. Upon biofilm disruption, bacteria regain antibiotic susceptibility. The drug is currently in phase I stage of clinical trial evaluation to treat Methicillin-resistant Staphylococcus aureus infections. TRL1068 has received more than $5M in grant funding from the NIH to facilitate preclinical development, including multiple animal proof-of-concept experiments.

  • Delpazolid (LCB01-0371): LegoChem Biosciences

Delpazolid (LCB01 0371) is an oxazolidinone derivative antibacterial therapeutic, being developed by LegoChem Biosciences to treat Tuberculosis, Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections.

 

Learn more about Methicillin-Resistant Staphylococcus Aureus Infection Drugs opportunities in our groundbreaking Methicillin-Resistant Staphylococcus Aureus Infection Research and development projects @ Methicillin-Resistant Staphylococcus Aureus Infection Unmet Needs

 

Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

 

Methicillin-Resistant Staphylococcus Aureus Infection Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Discover the latest advancements in Methicillin-Resistant Staphylococcus Aureus Infection Treatment by visiting our website. Stay informed about how we’re transforming the future @ Methicillin-Resistant Staphylococcus Aureus Infection Market Drivers and Barriers, and Future Perspectives

 

Scope of the Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Report

  • Coverage- Global
  • Methicillin-Resistant Staphylococcus Aureus Infection Companies- Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
  • Methicillin-Resistant Staphylococcus Aureus Infection Therapies- Retapamulin, Linezolid (Zyvox), Vancomycin, Nitric Oxide, Ceftaroline fosamil, Daptomycin, and others.
  • Methicillin-Resistant Staphylococcus Aureus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Methicillin-Resistant Staphylococcus Aureus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Methicillin-Resistant Staphylococcus Aureus Infection Pipeline on our website @ Methicillin-Resistant Staphylococcus Aureus Infection Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Methicillin-Resistant Staphylococcus Aureus Infections: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Methicillin-Resistant Staphylococcus Aureus Infections – DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. HY-004: Helperby therapeutics
  9. Drug profiles in the detailed report…..
  10. Early Stage Products (Phase I)
  11. TRL1068: Trellis Bioscience
  12. Drug profiles in the detailed report…..
  13. Preclinical and Discovery Stage Products
  14. EVX B1: Evaxion Biotech
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
  18. Methicillin-Resistant Staphylococcus Aureus Infections Key Products
  19. Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
  20. Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
  21. Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
  22. Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
  23. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Methicillin-resistant Staphylococcus aureus (MRSA) Infection Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Tumor Ablation Market Business Analysis, Swot Profile, Current Developments, Strategies To Boost Industry Growth

“Tumor ablation market is primarily driven by the rising incidence of cancer globally. Tumor ablation is widely used for the treatment of lung cancer, liver cancer, prostate cancer, bone cancer, and kidney cancer among others. According to WHO, cancer was the major cause of death globally in 2020 -accounted for around 10 mn deaths.”
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall tumor ablation market and the subsegments.

Tumor Ablation Market in terms of revenue was estimated to be worth $0.8 billion in 2024 and is poised to reach $1.4 billion by 2029, growing at a CAGR of 10.0% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Technological advancement, new product developments in cryoablation, and the rising incidence of cancer are the major indicators contributing to the growth of the market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142550258

Microwave ablation segment to register significant growth rate over the forecast period of 2024-2029.

Based on the technology, the global market is further segmented into microwave, radiofrequency, high-intensity focused ultrasound, cryoablation, and other technologies. The microwave ablation segment is anticipated to register the highest growth rate over in the near future owing to the promising results of the treatment. This is attributed to the increasing focus on microwave ablation due to its notable benefits such as speed, improved success rate and precise ablation. High efficiency rate of microwave ablation for various cancers is expected to increase its utilization in the end user facilities in coming years.

The generators segment will register a significant growth rate over the forecast period of 2024-2029.

The global tumor ablation market is segmented by product type into generators and probes/electrodes. Major shares of the segment are attributed to the rising patient population and rising adoption of ablation treatment globally. Increasing cancer population due to change in lifestyle, rising obesity, and increasing alcohol consumption contributes to the rise in the number of ablation procedures at hospitals and clinics. The rise in the number of procedures performed will ultimately support the growth of generators segment and is expected to register the significant growth during the forecast period.

Percutaneous ablation segment to register a significant growth rate over the forecast period of 2024-2029.

In terms of mode, global tumor ablation market is divided by mode of treatment into surgical, percutaneous, and laparoscopic ablation. In 2023, the surgical ablation segment held the major share of the market.  Increasing healthcare expenditure and cancer awareness campaigns support the growth of this segment. Educating people through various campaigns for the importance of early detection has been responsible for rise in the number of cancer screening in end user facilities. This ultimately supports the increasing number of ablation procedures and contributes to the exponential growth of the segment.

Liver cancer segment is in application to register a significant growth over the forecast period of 2024-2029.

By application, the global tumor ablation market is segmented by application into liver cancer, lung cancer, kidney cancer, bone cancer, and other applications. The growing trend towards ablation technology over traditional treatments and rising public awareness drive this segment’s growth. Consistent rise in the global cases of hepatocellular carcinoma, clinical studies showing improved success rate, and rising proportion of older age population have supported the growth of liver cancer segment in tumor ablation market.

The hospitals and clinics accounted for the major share of tumor ablation market by end user in 2023.

Based on end users, the tumor ablation market is segmented into hospitals & clinics, cancer care centers, and other end users. The major share of the end-user segment was held by hospitals and clinics in 2023. The increasing prevalence of liver cancer, advancements in tumor ablation technology, and a growing emphasis on non-invasive treatment options contribute to the expanding utilization of ablation treatment within healthcare settings for comprehensive patient care.

The Asia Pacific market will register significant growth in the market during the forecast period.

The Asia Pacific tumor ablation market is estimated to register significant growth from 2024 to 2029. The increasing target patient population, favorable reimbursement scenario, and growing disposable income fuel the APAC region’s market growth. Moreover, the APAC region has experienced a rise in investments by governments and major players, offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=142550258

Tumor Ablation Market Dynamics:

Drivers:

  1. Increasing cancer incidence and rising geriatric population

Restraints:

  1. Increasing cancer incidence and rising geriatric population

Opportunities:

  1. Rising healthcare expenditure across emerging economies

Challenge:

  1. Rising adoption of refurbished tumor ablation systems

Key Market Players of Tumor Ablation Industry:

As of 2023, prominent players in the tumor ablation market are Medtronic Plc (Ireland), Johnson & Johnson MedTech (US), and Stryker Corporation (US).

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
  • By Designation: Director-level–10%, C-level–14%, and Others–76%
  • By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=142550258

Tumor Ablation Market – Key Benefits of Buying the Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall tumor ablation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

  • Analysis of key drivers (increasing cancer incidence and rising geriatric population, rising focus on minimally invasive procedures, technological advancements in the field of tumor ablation, rising number of awareness campaigns and early detection), restraints (high cost of tumor ablation systems, unfavorable reimbursement scenario), opportunities (rising healthcare expenditure across emerging countries, increasing number of hospitals), and challenges (rising adoption of refurbished tumor ablation systems, hospital budget cuts) influencing the growth of the tumor ablation market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the tumor ablation market
  • Market Development: Comprehensive information about lucrative markets–the report analyses the tumor ablation market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tumor ablation market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players – such as Johnson & Johnson (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US) among others.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/tumor-ablation-market-142550258.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tumor Ablation Market Business Analysis, Swot Profile, Current Developments, Strategies To Boost Industry Growth

A Magical Adventure of Kindness and Courage: Ivo Ten Voorde’s ‘Charlotte and the Invitation to the Palace’ Inspires Young Readers

A Magical Adventure of Kindness and Courage: Ivo Ten Voorde’s ‘Charlotte and the Invitation to the Palace’ Inspires Young Readers

Charlotte and the Invitation to the Palace’ by Ivo Ten Voorde is a touching tale of generosity, bravery, and miraculous discoveries that young readers are about to experience. This charming children’s book, appropriate for readers aged 4 to 8, vividly illustrates the story of a courageous young girl whose deeds of kindness lead to amazing experiences in a royal castle.

Six-year-old Charlotte, a strong and sensitive girl, is at the heart of this endearing tale. She finds a white cat that is being tormented by vicious rodents. Charlotte’s instinctive goodness forces her to step in and protect the terrified cat from more damage without hesitation. She has no idea that this modest act of bravery leads to an amazing royal castle teeming with life, excitement, and brand-new acquaintances.

Readers are taken to a world of wonder as Charlotte enters the palace, where gregarious cats greet her with open arms, beautiful dancers spin through the corridors, and animated palace attendants scurry about. This enchanted location, full of colorful characters and breathtaking scenery, teaches Charlotte and readers alike that bravery and deeds of kindness can result in amazing and unanticipated benefits.

Through Charlotte’s character, author Ivo Ten Voorde effectively conveys the idea of bravery and compassion. ‘Charlotte and the Invitation to the Palace’ is a potent reminder that being kind and brave may lead to amazing adventures in a world where kids are frequently faced with decisions and obstacles. Children and adults alike find great resonance in the idea that kindness matters and has the capacity to transform lives.

The vivid pictures in the book give the narrative an additional element of enchantment, bringing it to life on each page. Charlotte’s world is brought to life for readers with each artwork, from the imposing royal palace to the vibrant scenes involving dancers and palace servants. The purity of youth and the attraction of learning something novel and wonderful are both portrayed in the artwork.

More than just a tale, ‘Charlotte and the Invitation to the Palace’ serves as a tool for instilling in kids a sense of bravery, empathy, and camaraderie. It acts as a springboard for deep talks on the value of lending a hand to others, facing fear head-on, and relishing the excitement of meeting new friends between parents and their kids. Children will want to read this classic story again and again, making it a priceless addition to any family’s collection.

Head to Amazon and order your book from today!

About the Author:

Ivo ten Voorde is an author and illustrator dedicated to sparking the imaginations of children aged 4 to 8. Drawing inspiration from his daughter’s creativity, Ivo crafts vibrant, heartwarming stories that celebrate imagination, curiosity, and adventure

Book Name: Charlotte and the invitation to the palace

Author Name: Ivo Ten Voorde

ISBN Number: 1917438508

Kindle Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Books Publishing Company
Email: Send Email
Phone: +1-213-734-5718
Address:2425 West Loop South
City: Houston
State: Texas
Country: United States
Website: https://bookspublishingcompany.com

Unlocking the Secrets to Business Success: ‘Business is War’ by Elliott Forman

Unlocking the Secrets to Business Success: 'Business is War' by Elliott Forman

Elliott Forman presents a road map for corporate success in his gripping new book, ‘Business is War,’ which goes beyond conventional thinking and places a strong emphasis on the crucial function of cash flow management. Elliot Forman highlights the transformational impact of seeing money not just as a goal but as a strategic tool for sustainable progress, drawing on Benjamin Franklin’s ageless wisdom.

The core of ‘Business Is War’ is a deep comprehension of how careful financial management may determine a company’s course. The author, Elliot Forman, walks readers through the subtleties of capital management while arguing for a comprehensive strategy that strikes a balance between building capital through organic means and prudently leveraging it through strategic borrowing.

This book provides executives and business owners with useful information on determining capital requirements, calculating returns on investment, and making wise financial decisions that support long-term success. He contends that this strategy is essential for grasping possibilities and successfully addressing obstacles that emerge in the cutthroat corporate environment of today.

This compelling book, ‘Business Is War’ by Elliott Forman, explores the psychology of corporate leadership beyond financial ability, emphasizing the value of self-belief and tenacity in conquering challenges. The author also demonstrates how developing robust business models that flourish in the face of adversity requires strategic decision-making across critical business activities, from scaling plans to marketing approaches.

This book also aims to empower individuals to harness the full potential of their businesses by mastering the art of financial agility and strategic foresight. ‘Business is War’ is an indispensable tool for entrepreneurs seeking to grow their businesses to greater heights of success, thanks to its thorough yet approachable insights.

The wisdom encapsulated in this book will help the readers negotiate the intricacies of modern business and attain sustainable growth, regardless of their experience level as entrepreneurs or aspiring startup founders.

‘Business is War’ is for individuals prepared to revolutionize their business processes and welcome a future characterized by strategic acumen and financial fortitude. Order your copy from Amazon, and let’s start the path to discovering the keys to long-term company success.

About the Author:

Elliott Forman is a retired professional boxer turned entrepreneur. He founded Bonita Payments in 2014 after a decorated corporate career. His passions are golf, supercars, working out, and miniature schnauzers. You can find him at a local coffee shop, deep into a book, or just Thinking of his Master Plan. He currently lives in New Orleans, his hometown, with his family.

Book Name: Business is War: Tactics for a Winning Strategy

Author Name: Elliott Forman

ISBN Number:  1963911520

Kindle Version: Click Here

Paperback Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Book Publishing Pros
Email: Send Email
Phone: +1-213-734-5715
Address:17595 Harvard Ave, Ste C-641
City: Irvine
State: California
Country: United States
Website: https://bookpublishingpros.co

Spinal Muscular Atrophy Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Spinal Muscular Atrophy Pipeline Insight 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal muscular atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Spinal Muscular Atrophy Research. Learn more about our innovative pipeline today! @ Spinal Muscular Atrophy Pipeline Outlook

 

Key Takeaways from the Spinal Muscular Atrophy Pipeline Report

  • In October 2024:- Hoffmann-La Roche- This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children < 2 years of age genetically diagnosed with SMA.
  • In October 2024:- Lantu Biopharma- Study duration per participant is approximately 25 months including an approximately 30-day screening/baseline period, an approximately 24-month study observation period including 1 treatment day, and an approximately 24-month follow-up period. Patients will be tested at baseline and return for follow-up visits twice a week through the first month post dose, and followed by visits at months 2, 3, 6 12, 18 and 24 post infusion. Unscheduled visits may occur if the investigator determines that they are necessary.
  • In October 2024:- Genentech Inc.- A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments.
  • DelveInsight’s Spinal Muscular Atrophy pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Spinal Muscular Atrophy treatment.
  • The leading Spinal Muscular Atrophy Companies such as Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others.
  • Promising Spinal Muscular Atrophy Therapies such as Risdiplam, Nusinersen, Vesemnogene Iantuparvovec, OAV101, NMD670, GC101, Apitegromab, and others.

 

Stay informed about the cutting-edge advancements in Spinal Muscular Atrophy Treatments. Download for updates and be a part of the revolution in care @ Spinal Muscular Atrophy Clinical Trials Assessment

 

Spinal Muscular Atrophy Emerging Drugs Profile

  • Apitegromab: Scholar Rock

Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA. The US Food and Drug Administration (FDA) has granted Fast Track (FTD), Orphan Drug (ODD) and Rare Pediatric Disease (RPD) designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. Currently, it is in phase III stage of development.

  • ACTX-401: Alcyone Therapeutics

ACTX-401 is an AAV9-delivered gene replacement therapy for the treatment of a rare form of Spinal Muscular Atrophy (SMA) called SMA with Respiratory Distress type 1 (SMARD1), and for Charcot-Marie-Tooth type 2S (CMT2S). SMARD1 and CMT2S are autosomal recessive genetic disorders caused by mutations in the gene that produces immunoglobulin mu-binding protein 2 (IGHMBP2) and are part of a larger family of disorders called IGHMBP2-related disorders (IRDs). ACTX-401 delivers a functional copy of the IGHMBP2 gene to patients, restoring expression of functional IGHMBP2. ACTX-401 clinical success in SMARD1 and CMT2S could lead to applicability to other IRDs in the future. Currently, it is being investigated in Phase I/II stage of development for the treatment of spinal muscular atrophy.

 

Learn more about Spinal Muscular Atrophy Drugs opportunities in our groundbreaking Spinal Muscular Atrophy Research and development projects @ Spinal Muscular Atrophy Unmet Needs

 

Spinal muscular atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Spinal Muscular Atrophy Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Discover the latest advancements in Spinal Muscular Atrophy Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Spinal Muscular Atrophy Market Drivers and Barriers, and Future Perspectives

 

Scope of the Spinal Muscular Atrophy Pipeline Report

  • Coverage- Global
  • Spinal Muscular Atrophy Companies- Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others.
  • Spinal Muscular Atrophy Therapies- Risdiplam, Nusinersen, Vesemnogene Iantuparvovec, OAV101, NMD670, GC101, Apitegromab, and others.
  • Spinal Muscular Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Spinal Muscular Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Spinal Muscular Atrophy Pipeline on our website @ Spinal Muscular Atrophy Drugs and Companies

 

Table of Content

  1. Executive Summary
  2. Spinal muscular atrophy: Overview
  3. Pipeline Therapeutics
  4. Therapeutic Assessment
  5. Spinal muscular atrophy – DelveInsight’s Analytical Perspective
  6. Late Stage Products (Phase III)
  7. Apitegromab: Scholar Rock
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Branaplam: Novartis
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I/II)
  13. ACTX 401: Alcyone Therapeutics
  14. Drug profiles in the detailed report….
  15. Inactive Products
  16. Spinal muscular atrophy- Unmet Needs
  17. Spinal muscular atrophy- Market Drivers and Barriers
  18. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

How to choose a marketing agency?, by Relevant Audience

How to choose a marketing agency?, by Relevant Audience

Currently, having a prominent online presence is a fundamental element for the success of businesses across multiple sectors. In this sense, it is key to position correctly to reach each business’s target audience. Additionally, to achieve quality results, it is advisable to seek the support of specialists.

In this regard, Relevant Audience is a marketing agency in Bangkok that offers comprehensive services to a broad portfolio of clients. This company specializes in optimizing the positioning and visibility of online businesses.

Key aspects when choosing a marketing agency

There are several determining factors to consider when selecting an appropriate marketing agency. One of the most important is defining specific objectives and needs, ensuring they are realistic, measurable, relevant, and time-bound.

Furthermore, it is essential to research the track record of each agency. For example, Relevant Audience is a Bangkok marketing agency known for its solid trajectory. It also has a team of qualified professionals who work to achieve growth in their clients’ businesses.

Analyzing the company’s digital image and presence is another key step in choosing a marketing agency, including its relationship with previous clients. It is also crucial to select a company that stands out for its flexibility and ability to adapt to change. This is a key aspect in today’s environment.

Developing creative and original strategies

Another essential element when searching for a marketing agency is creativity and originality. In this regard, communication and marketing strategies must follow these parameters to achieve optimal results. Additionally, it is important to develop an analytical approach and have the ability to reach goals based on each client’s commercial and organizational objectives.

Finally, choosing a company that can offer personalized and tailored services is essential to ensure a successful digital transformation. This way, it is possible to grow a business online.

In short, with the support of Relevant Audience, a company can improve its online positioning and expand its visibility. This marketing agency in Bangkok is known for applying a results-oriented and 100% transparent methodology.

Media Contact
Company Name: Relevant Audience Co., LTD
Contact Person: Press Office
Email: Send Email
Country: United States
Website: https://www.relevantaudience.com/

Unlocking Business Success: ‘Business is War’ by Elliott Forman Offers Essential Insights into Mastering Cash Flow and Strategic Growth

Unlocking Business Success: ‘Business is War’ by Elliott Forman Offers Essential Insights into Mastering Cash Flow and Strategic Growth

Understanding the fundamentals of financial management is essential for long-term success and sustainable growth in the cutthroat business environment of today. Elliott Forman’s most recent book, ‘Business is War,’ emphasizes the vital role that cash flow management plays as the cornerstone of profitability and offers a thorough roadmap for navigating the complexity of business finance.

The author walks readers through the transformation of money from a mere commodity to a strategic instrument for driving corporate expansion by drawing on ageless wisdom and useful tactics. In line with Benjamin Franklin’s proverb, ‘Beware of little expenses; a small leak will sink a great ship,’ Elliot Forman emphasizes the significance of careful financial management, enabling business owners to spot and fix possible money pits that could endanger their ventures.

 ‘Business is War’ gives business leaders the courage to face obstacles head-on by empowering them to handle financial details with confidence and forethought. The book explores the essential mechanics of acquiring money, making a distinction between strategic borrowing and organic growth. Forman skillfully leads readers through the process of evaluating capital requirements, computing investment returns, and making well-informed decisions regarding borrowing and investing.

Forman’s approach to capital management, which demystifies the process of properly accessing and managing capital, lies at the heart of the book. Through the differentiation of organic earnings from strategic borrowing, readers acquire the ability to assess their capital requirements, compute investment returns, and make well-informed judgments that are essential for capitalizing on expansion prospects and surmounting business obstacles.

Beyond financial know-how, ‘Business is War’ fosters the resilient and strategically minded mindset necessary for sustained success. With Forman’s insights into sales techniques, marketing breakthroughs, and scaling strategies, readers will be better able to create strong business models that outperform rivals in their industry.

If you are someone looking to transform their business, this book will be a game-changer. This book perfectly emphasizes that managing money isn’t enough; we also need to use it to fuel innovation and sustainable growth.

‘Business is War’ is an invaluable tool for executives, seasoned business owners, and aspiring entrepreneurs to use when navigating the intricacies of the modern economic environment.

The author, Elliot Forman, emphasizes useful guidance and real-world examples and is well-positioned to enable readers to grow their enterprises to unprecedented levels. Don’t miss the chance to order your copy from Amazon today.

About the Author:

Elliott Forman is a retired professional boxer turned entrepreneur. He founded Bonita Payments in 2014 after a decorated corporate career. His passions are golf, supercars, working out, and miniature schnauzers. You can find him at a local coffee shop, deep into a book, or just Thinking of his Master Plan. He currently lives in New Orleans, his hometown, with his family.

Book Name: Business is War: Tactics for a Winning Strategy

Author Name: Elliott Forman

ISBN Number:  1963911520

Kindle Version: Click Here

Paperback Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Book Publishing Pros
Email: Send Email
Phone: +1-213-734-5715
Address:17595 Harvard Ave, Ste C-641
City: Irvine
State: California
Country: United States
Website: https://bookpublishingpros.co

New Book Chronicles The Legendary History Of The 69th Infantry Regiment

New Book Chronicles The Legendary History Of The 69th Infantry Regiment

James P. Tierney is proud to announce the release of his new book, From Dublin, to Bull Run, to Baghdad and Beyond: The Story of the Fighting 69th. This comprehensive history brings to life the incredible story of one of America’s most famous military units, tracing its roots from Irish immigrant militias in 1849 to its modern-day service in Operation Iraqi Freedom.

The 69th Infantry Regiment, famously known as “The Fighting 69th,” has a storied legacy of valor and sacrifice. It began with Irish immigrants fighting for respect and recognition in the United States and evolved into one of the most respected units in the U.S. military. In From Dublin, to Bull Run, to Baghdad and Beyond: The Story of the Fighting 69th, Tierney captures the unique identity and profound impact of the regiment over more than a century of military service.

“More than just a military unit, the 69th is a symbol of Irish-American pride and resilience,” said Tierney. “This book is a tribute to the courage, sacrifice, and unbreakable bonds that have been passed down through generations of soldiers.”

Tierney, a retired Colonel and longtime historian of the 69th Infantry Regiment, brings a wealth of knowledge to this project. Having served as the regiment’s historian and participated in several key military operations, including Operation Desert Storm, Tierney offers an insider’s perspective on the regiment’s evolution and contributions to major historical conflicts.

About the Author:

James P. Tierney is a retired U.S. Army Colonel who served as a historian for the 69th Infantry Regiment. His deep connection to the regiment is personal—his father and uncles were members, and he himself served for several years. Tierney has been a featured expert on the History Channel and is a distinguished member of various military and veteran organizations. From Dublin, to Bull Run, to Baghdad and Beyond: The Story of the Fighting 69th is a culmination of decades of research and personal experience.

Book Name: From Dublin to Bull Run to Baghdad and Beyond: The Story of the Fighting 69th

Author Name: James P. Tierney

ISBN Number: 1917553013

Kindle Version: Click Here

Paperback Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Book Publishing Plus
Contact Person: Book Publishing Plus
Email: Send Email
Phone: +1-201-977-0753
Address:100 Overlook Center
City: Princeton
State: New Jersey
Country: United States
Website: https://bookpublishingplus.com/

Johnny Lappin Releases Memoir, In a Lifetime: From Hozier to U2 – Offers A Deep Look At The Rise of Irish Music on the Global Stage

Johnny Lappin Releases Memoir, In a Lifetime: From Hozier to U2 - Offers A Deep Look At The Rise of Irish Music on the Global Stage

Johnny Lappin, one of Ireland’s most distinguished music publishers and a driving force behind some of the nation’s most successful musical exports, is here to enlighten readers with his memoir, “In a Lifetime: From Hozier to U2.”

With over 45 years of experience in the music industry, Lappin’s story is a compelling narrative that blends personal insight, industry history, and captivating anecdotes from his illustrious career. This book serves as a rare insider’s guide to the complex world of music publishing while also shedding light on the incredible evolution of Irish music from its local roots to global acclaim.

In In a Lifetime, Lappin offers an unfiltered view of the Irish music industry’s transformation over four decades, detailing his pivotal role in shaping the international careers of artists like Clannad, Celtic Woman, Picture This, and Grammy-nominated Hozier. Known for his tenacity, strategic thinking, and passion for preserving the integrity of Irish music, Lappin shares the untold stories behind iconic tracks such as Theme from Harry’s Game and Hozier’s Take Me to Church. He provides readers with a front-row seat to the high-stakes negotiations, relentless lobbying for artists’ rights, and the delicate balancing act required to navigate an ever-changing global music landscape.

Music publishing has been Johnny’s lifelong passion, and this memoir is not just a reflection on his career but a celebration of the talent, creativity, and resilience that define Irish music.

Johnny Lappin’s career began in the late 1970s, a time when the Irish music scene was just beginning to find its footing in the global arena. He co-founded Scoff Records, one of Ireland’s first independent rock labels, and later became a founding Director of IMRO (Irish Music Rights Organisation). His strategic foresight and unwavering dedication have made him a key player in the success of numerous Irish acts, and his influence continues to shape the industry today through his ongoing work with the Mechanical Copyright Society of Ireland (MCPSI) and the Music Publishers Association of Ireland (MPAI).

In In a Lifetime,” reflects on the evolution of music publishing, from the days of vinyl and cassettes to the digital era of streaming and downloads. Lappin discusses the shifting dynamics of the industry, the battles for fairer copyright laws, and the ever-present need to protect the rights of songwriters. His book is not just a memoir—it’s a testament to the power of music, the importance of artistic integrity, and the crucial role of publishers in nurturing and sustaining the creative community.

Praised for its candid and engaging narrative, In a Lifetime is a must-read for music enthusiasts, industry professionals, and anyone curious about the stories that shaped Ireland’s rich musical heritage.

Johnny Lappin’s memoir is now available in print and eBook formats on Amazon https://www.amazon.com/dp/179664403X, and an audiobook version is set for release in the upcoming future.

About the Author:

Johnny Lappin is an award-winning music publisher with over four decades of experience in the Irish and international music scenes. A champion of Irish songwriters, Lappin has worked with artists such as Hozier, Clannad, Celtic Woman, and many more. He is a founding Director of the Irish Music Rights Organisation (IMRO) and serves as Chairman of the Mechanical Copyright Society of Ireland (MCPSI). His dedication to protecting the rights of songwriters has made him a respected figure in the global music community. In a Lifetime: From Hozier to U2 is his second book, following The Need to Know Guide to Music Publishing.

Book Name: In A Lifetime

Author Name: Johnny Lappin

ISBN Number: 179664403X

Kindle Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Book Publishing Pros
Email: Send Email
Phone: +1-213-734-5715
Address:17595 Harvard Ave, Ste C-641
City: Irvine
State: California
Country: United States
Website: https://bookpublishingpros.co